TABLE 3.
Multivariable analysis depicting factors associated with persistent cGVHD after adjusting for factors in the univariate analysis: bone marrow stem cell source, presence of ENA autoantibodies, higher NIH lung score, higher platelet count and higher IgA. Standard estimate stands for parameter estimate that is part of a model predicting patients with persistent cGVHD. The higher the value, the stronger the contribution of that variable to the model
| Parameter | DF | Estimate | Standard error | Wald Chi-square | P value |
|---|---|---|---|---|---|
| Intercept | 1 | −6.35 | 1.33 | 22.71 | <.0001 |
| Bone marrow (BM) stem cells | 1 | 1.85 | 0.67 | 7.71 | .006 |
| ENA autoantibody | 1 | 4.06 | 1.37 | 8.76 | .003 |
| NIH lung score | 1 | 1.02 | 0.36 | 7.96 | .005 |
| Platelets | 1 | 0.0077 | 0.0032 | 5.83 | .016 |
| IgA | 1 | 0.015 | 0.0045 | 11.97 | <.001 |
Estimates represent the difference in log(odds) or log(odds ratio). Estimates correspond to the following comparisons: patients who received bone marrow stem cells vs. patients who received peripheral blood or cord blood stem cells; patients with detectable extractable nuclear antigen (ENA) antibodies vs. patients with undetectable antibodies; patients who differ by one stage of NIH lung score; patients who differ by 109/L platelets; and patients who differ by 1mg/dL of IgA.